Moderna Stops mRNA COVID Biologics Plant Construction in Kenya
Moderna, Inc. announced recently that it has suspended its efforts to build a $200–$500 million mRNA (messenger ribonucleic acid) biologics manufacturing facility in Kenya while it determines projected future demand for mRNA biologics in Africa. Company officials concluded that, since the end of the COVID pandemic, interest in COVID-19 biologics in Kenya and Africa has […]
The Naked Absurdity of Global Public Health
Opinion | Something is fundamentally wrong with global public health. More accurately, something is fundamentally wrong with the mindset of global health professionals, particularly those in positions of leadership. It has become normal to speak, repeat, and defend complete absurdity, as if illusions and fantasies are real. There are no sanctions for operating in this […]
Study Reveals Much Higher Risk for Serious Adverse Events With mRNA COVID Shots in Clinical Trials
A new study published in the journal Vaccine revealed there was a much higher risk of serious adverse events of special interest for randomized clinical trial participants who received a messenger RNA (mRNA) COVID-19 biologic when compared to participants, who received a placebo for both the Pfizer/BioNTech mRNA BNT162b2 (also known as “Comirnaty”) COVID shot […]
Tanzanian Government Skeptical About Safety of COVID-19 Vaccines
On Feb 2, 2021, Tanzania’s health minister, Dorothy Gwajima, announced that her country has no plans in place to recommend widespread use of COVID-19 vaccines in the African country.1 The announcement came a few days after Tanzania’s President John Magufuli expressed concern about the safety and effectiveness of COVID-19 vaccines developed and manufactured in Western […]
Children Recruited in U.K. for COVID-19 Vaccine Trial
The University of Oxford’s Jenner Institute and Oxford Vaccine Group in the United Kingdom has announced that its researchers have begun recruiting children aged five to 12 years for phase II and phase III clinical trials testing an experimental COVID-19 vaccine the university is developing in partnership with AstraZeneca plc.1 Oxford’s ChAdOx1 nCov-19 (“chimpanzee adenovirus […]
Pfizer/BioNTech Target Fall 2020 for COVID-19 Vaccine Availability
In recent weeks Inovio Pharmaceuticals of Pennsylvania and representatives of the German biotechnology firm CureVac AG and the University of Oxford in the United Kingdom have announced that their experimental COVID-19 vaccines will be ready for use by September 2020. On Apr. 29, 2020, Pfizer, Inc. of New York stated in a news release that […]